KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial.

Bruce E Sands, David T Rubin, Edward V Loftus, Douglas C Wolf, Remo Panaccione, Jean-Frederic Colombel, Axel Dignass, Miguel Regueiro, Severine Vermeire, Anita Afzali, Garrett Lawlor, Harris A Ahmad, Hsiuanlin Wu, Mark T Osterman, Anjali Jain, Geert D'Haens

Am J Gastroenterol 120(10) 2339-2349

PMID39773524
PMCIDPMC12487659
DOI10.14309/ajg.0000000000003310
发表日期2025-01-08
入排依据:未发现恶性肿瘤人群证据。
已检查 7 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;另有 2 张未列出。
摘要

摘要

INTRODUCTION: Patients with ulcerative colitis (UC) and prior biologic failure may have reduced or delayed efficacy with subsequent advanced therapies. This analysis evaluated the efficacy and safety of ozanimod during the True North (TN) study and its open-label extension (OLE) in biologic-exposed patients with UC. METHODS: TN was a randomized, placebo-controlled 52-week trial (10-week induction, 42-week maintenance period). Eligible patients could enter the OLE. Clinical outcomes were assessed at TN week (W) 10 and W52 and OLE W46 and W94. Symptomatic efficacy was evaluated through induction and in the OLE until W94. Safety was assessed. RESULTS: This analysis included 376 biologic-exposed patients. In the placebo-controlled cohort, more ozanimod-treated patients achieved clinical response than placebo at W10 regardless of the number or type of prior biologics; patients who used 1 vs ≥2 prior biologics achieved higher efficacy rates. Efficacy rates were higher at W52 than W10 and were similar across subgroups regardless of the number or type of prior biologics. Significantly greater proportions of ozanimod vs placebo patients achieved symptomatic response by W5 ( P = 0.0173) and symptomatic remission by W10 ( P = 0.0207). Among biologic-exposed TN W10 ozanimod nonresponders who entered the OLE, 61% achieved symptomatic response with an extra 10 weeks of ozanimod treatment. Ozanimod efficacy was durable for ∼3 years of continuous treatment in biologic-exposed W52 clinical responders who entered the OLE. No new safety signals were observed. DISCUSSION: Ozanimod was effective and safe in biologic-exposed patients with UC, but these patients may require more time to respond to treatment. Clinical trial registry website and trial numbers: ClinicalTrials.gov , numbers NCT02435992 and NCT02531126.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. Efficacy of ozanimod vs placebo by the number of prior biologics in biologic-exposed patients. ( a ) Efficacy at week 10 of the IP by 1 biologic and ≥2 biologics. ( b ) Efficacy at week 52 of the MP by 1 biologic and ≥2 biologics. “Δ” represents the difference between ozanimod and placebo in cohort 1 of the IP and between ozanimod (ozanimod/ozanimod) and placebo (ozanimod/placebo) in the MP. CI, confidence interval; IP, induction period; MP, maintenance period.
非 KM Figure
Figure 2Figure 2. Ozanimod efficacy by prior biologic type. ( a ) Week 10 efficacy outcomes in patients previously exposed to anti-TNFs, vedolizumab, or both. ( b ) Week 52 efficacy outcomes in patients previously exposed to anti-TNFs, vedolizumab, or both. “Δ” represents the difference between ozanimod and placebo in cohort 1 of the IP and between ozanimod (ozanimod/ozanimod) and placebo (ozanimod/placebo) in the MP. CI, confidence interval; CS, corticosteroid; IP, induction period; MP, maintenance period; NE, not estimable; TNF, tumor necrosis factor.
非 KM Figure
Figure 3Figure 3. Onset of action. ( a ) Symptomatic response and ( b ) symptomatic remission during the IP of True North. Shading represents the 1-week dose titration of ozanimod. IP, induction period.
非 KM Figure
Figure 4Figure 4. Symptomatic efficacy from OLE week 5 to week 94 in biologic-exposed patients who were TN week 10 ozanimod clinical nonresponders and subsequently entered the OLE for extended induction treatment with ozanimod. ( a ) OC and ( b ) NRI analyses. Denominators for the OC (n) analyses were based on the numbers of patients who completed the OLE timepoint and had data available for the endpoints in question. Denominators for the NRI analyses (n) were based on the numbers of patients who completed the OLE timepoint or discontinued ozanimod. NRI, nonresponder imputation; OC, observed case; OLE, open-label extension; TN, True North; W, week.
非 KM Figure
Figure 5Figure 5. Efficacy at OLE weeks 46 and 94 in biologic-exposed patients who were TN week 10 ozanimod clinical nonresponders and subsequently entered the OLE for extended induction treatment with ozanimod. ( a ) OC and ( b ) NRI analyses. Denominators for the OC analyses were based on the numbers of patients who completed OLE weeks 46 or 94 and had data available for the endpoints in question. Denominators for the NRI analyses were based on the numbers of patients who completed OLE week 46, completed OLE week 94, or discontinued ozanimod treatment. CS, corticosteroid; NRI, nonresponder imputation; OC, observed case; OLE, open-label extension; TN, True North; W, week.
非 KM Figure
Figure 6Figure 6. Efficacy at OLE weeks 46 and 94 in biologic-exposed patients who were TN week 52 ozanimod clinical responders and subsequently entered the OLE. ( a ) OC and ( b ) NRI analyses. CS, corticosteroid; NRI, nonresponder imputation; OC, observed case; OLE, open-label extension; TN, True North.
非 KM Figure